Published in Pharmazie on May 01, 1995
Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med (1989) 2.51
Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol (1991) 2.07
Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology (1989) 1.91
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther (2009) 1.66
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53
Proton MR spectroscopy of the brain: clinically useful information obtained in assessing CNS diseases in children. AJR Am J Roentgenol (1996) 1.47
Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol (1983) 1.43
Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med (1989) 1.43
Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol (2009) 1.41
Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res (1999) 1.41
Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol (1992) 1.40
[Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma]. Pneumologie (1998) 1.39
Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. Eur J Clin Pharmacol (2013) 1.35
Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. Br J Anaesth (2000) 1.33
A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol (1990) 1.31
Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J (1997) 1.26
Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother (1992) 1.25
Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg (1996) 1.24
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther (2008) 1.23
Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics (1999) 1.23
The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J (2007) 1.21
Pharmacokinetics of inhaled anaesthetics in a clinical setting: description of a novel method based on routine monitoring data. Br J Anaesth (2000) 1.20
Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin (2010) 1.20
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol (1988) 1.14
Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol (1993) 1.12
Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn Reson Med (1989) 1.08
Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol (1990) 1.08
A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients. Am J Respir Crit Care Med (1999) 1.07
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther (2010) 1.06
IgA deficiency, epilepsy, and hydantoin medication. Lancet (1976) 1.03
Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm (1992) 1.02
Repaglinide and related hypoglycemic benzoic acid derivatives. J Med Chem (1998) 1.01
Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy. Radiology (1991) 0.99
Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos (1991) 0.98
Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol (1992) 0.98
Clinical pharmacokinetics of urapidil. Clin Pharmacokinet (1988) 0.97
Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J (1992) 0.97
Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol (1989) 0.97
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics (1996) 0.96
A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol (1992) 0.95
Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV Med (2012) 0.95
Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol (1995) 0.94
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet (1992) 0.93
A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. AIDS Res Hum Retroviruses (1996) 0.92
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther (2010) 0.92
Localized proton NMR spectroscopy using stimulated echoes: applications to human skeletal muscle in vivo. Magn Reson Med (1991) 0.92
Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. Int J Clin Pharmacol Ther (2005) 0.92
Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol (1992) 0.91
Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man. Eur J Clin Pharmacol (1993) 0.91
Dermal absorption of permethrin following topical administration. Eur J Clin Pharmacol (2005) 0.90
Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled drug delivery device. Eur J Clin Pharmacol (1986) 0.90
Combined magnetic resonance imaging and proton magnetic resonance spectroscopy of patients with acute stroke. Stroke (1992) 0.89
Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J Magn Reson (1998) 0.89
Cartilage disorders: comparison of spin-echo, CHESS, and FLASH sequence MR images. Radiology (1987) 0.89
Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol (2000) 0.89
Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther (2000) 0.89
Directional decision for a two-tailed alternative. J Biopharm Stat (1996) 0.89
Generalization of distribution--free confidence intervals for bioavailability ratios. Eur J Clin Pharmacol (1985) 0.89
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol (2011) 0.89
Intra-individual variability of caffeine elimination in healthy subjects. Int J Clin Pharmacol Ther Toxicol (1992) 0.88
Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol (1991) 0.88
Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology (1998) 0.88
Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol (1991) 0.87
Measurements of morning and evening airflow grossly underestimate the circadian variability of FEV1 and peak expiratory flow rate in asthma. Am J Respir Crit Care Med (1995) 0.87
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos (2005) 0.87
Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther (2001) 0.87
Dynamic responses to intravenous urapidil and dihydralazine in normal subjects. Clin Pharmacol Ther (1985) 0.86
31P-spectroscopy of head and neck tumors--surface coil technique. Magn Reson Imaging (1989) 0.86
Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther (1998) 0.86
Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther (1996) 0.86
Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumors. MAGMA (1996) 0.86
Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Anticancer Res (1996) 0.85
Reference tables for the intrasubject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Ther (1995) 0.85
Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol (1994) 0.85
Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab (2010) 0.85
Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol (1996) 0.85
Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. Eur J Clin Pharmacol (1992) 0.85
Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther (1995) 0.84
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther (2007) 0.83
Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother (1987) 0.83
Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther (1995) 0.83
Bioequivalence studies: single vs multiple dose. Int J Clin Pharmacol Ther Toxicol (1992) 0.83
Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther (1994) 0.83
In vivo nuclear Overhauser effect in 31P-(1H) double-resonance experiments in a 1.5-T whole-body MR system. Magn Reson Med (1990) 0.83
[Gyrase inhibitors. Central nervous side effects and inhibition of methylxanthine elimination]. Dtsch Med Wochenschr (1990) 0.83
MR imaging of the normal shoulder. Radiology (1986) 0.82
Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther (2000) 0.82
Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther (1996) 0.81
Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis (1990) 0.81
Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol (1996) 0.81
1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med (1995) 0.81
Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther (1996) 0.81
Gyrase-inhibitors impair caffeine elimination in man. Methods Find Exp Clin Pharmacol (1987) 0.81